X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AUROBINDO PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AUROBINDO PHARMA PFIZER/
AUROBINDO PHARMA
 
P/E (TTM) x 32.9 14.8 222.8% View Chart
P/BV x 4.9 3.8 128.4% View Chart
Dividend Yield % 0.8 0.4 188.7%  

Financials

 PFIZER   AUROBINDO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-17
AUROBINDO PHARMA
Mar-17
PFIZER/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,055895 229.6%   
Low Rs1,651622 265.5%   
Sales per share (Unadj.) Rs429.8254.6 168.8%  
Earnings per share (Unadj.) Rs73.639.3 187.4%  
Cash flow per share (Unadj.) Rs87.446.6 187.6%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %1.10.3 327.5%  
Book value per share (Unadj.) Rs528.7160.0 330.5%  
Shares outstanding (eoy) m45.75585.88 7.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.33.0 144.7%   
Avg P/E ratio x25.219.3 130.4%  
P/CF ratio (eoy) x21.216.3 130.2%  
Price / Book Value ratio x3.54.7 73.9%  
Dividend payout %27.26.4 426.9%   
Avg Mkt Cap Rs m84,777444,390 19.1%   
No. of employees `0002.814.0 20.3%   
Total wages/salary Rs m3,03917,678 17.2%   
Avg. sales/employee Rs Th6,925.910,667.8 64.9%   
Avg. wages/employee Rs Th1,070.41,264.3 84.7%   
Avg. net profit/employee Rs Th1,186.31,645.8 72.1%   
INCOME DATA
Net Sales Rs m19,663149,157 13.2%  
Other income Rs m1,0121,159 87.3%   
Total revenues Rs m20,674150,316 13.8%   
Gross profit Rs m3,49134,343 10.2%  
Depreciation Rs m6294,276 14.7%   
Interest Rs m10667 1.4%   
Profit before tax Rs m3,86430,558 12.6%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,8017,597 23.7%   
Profit after tax Rs m3,36823,012 14.6%  
Gross profit margin %17.823.0 77.1%  
Effective tax rate %46.624.9 187.5%   
Net profit margin %17.115.4 111.0%  
BALANCE SHEET DATA
Current assets Rs m20,78992,062 22.6%   
Current liabilities Rs m7,87066,223 11.9%   
Net working cap to sales %65.717.3 379.3%  
Current ratio x2.61.4 190.0%  
Inventory Days Days60106 56.4%  
Debtors Days Days2268 33.1%  
Net fixed assets Rs m9,17562,919 14.6%   
Share capital Rs m458586 78.1%   
"Free" reserves Rs m23,73193,133 25.5%   
Net worth Rs m24,18993,719 25.8%   
Long term debt Rs m251,814 1.4%   
Total assets Rs m32,706162,494 20.1%  
Interest coverage x403.546.8 862.2%   
Debt to equity ratio x00 5.3%  
Sales to assets ratio x0.60.9 65.5%   
Return on assets %10.314.6 70.9%  
Return on equity %13.924.6 56.7%  
Return on capital %21.432.7 65.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6375,838 0.1%   
Fx outflow Rs m4,06730,224 13.5%   
Net fx Rs m-4,00445,613 -8.8%   
CASH FLOW
From Operations Rs m3,28832,786 10.0%  
From Investments Rs m-2,496-17,870 14.0%  
From Financial Activity Rs m-826-19,153 4.3%  
Net Cashflow Rs m-35-4,239 0.8%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 4.9 27.7 17.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.2 232.4%  
Shareholders   85,207 69,601 122.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 22, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS